TITLE:
"REDUCE" - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

CONDITION:
Neoplasms, Prostate

INTERVENTION:
Dutasteride

SUMMARY:

      This 4-year study will compare how safe and effective an oral investigational medicine is
      (compared to placebo) in preventing the development of prostate cancer in men that are
      defined by the study entrance criteria as being at an increased risk for prostate cancer.
      Study visits to the clinic will occur every 6 months for up to 4 years (10 clinic visits),
      and a prostate biopsy will be performed at 2 and 4 years of treatment.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Male
Age: 50 Years to 75 Years
Criteria:

        Inclusion criteria:

          -  Informed consent to participate in study.

          -  Have had a single negative prostate biopsy within 6 months prior to enrollment in
             study.

          -  Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a
             PSA between 3.0 and 10 if over age 60.

          -  Ability and will to participate in study for 4 years.

        Exclusion criteria:

          -  More than one previous negative prostate biopsy.

          -  History of prostate cancer.

          -  Previous prostate surgery.

          -  Inability to urinate requiring the need of a catheter during the previous 2 years.

          -  Any condition (other than benign prostatic hypertrophy) which may result in urinary
             symptoms or changes in urine flow rate.

          -  Cancer within previous 5 years (other than basal or squamous cell cancers of the
             skin).

          -  Any unstable serious medical condition.

          -  Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride
             (Avodart), testosterone, or drugs that can block the action of male hormones.
      
